These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21050790)

  • 21. [Blood donor hemovigilance: impact for donor and recipient safety].
    Hauser L; Beyloune A; Simonet M; Bierling P
    Transfus Clin Biol; 2013 May; 20(2):99-103. PubMed ID: 23587614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The French Haemovigilance System: organization and results for 2003.
    Rebibo D; Hauser L; Slimani A; Hervé P; Andreu G
    Transfus Apher Sci; 2004 Oct; 31(2):145-53. PubMed ID: 15501418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hospital haemovigilance and adverse events or reactions: who notifies and what?].
    Gouëzec H; Bazin A; Lassale B; Huchet C; Artéro N
    Transfus Clin Biol; 2012 Nov; 19(4-5):178-81. PubMed ID: 23043856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemovigilance procedure in transfusion medicine.
    Faber JC
    Hematol J; 2004; 5 Suppl 3():S74-82. PubMed ID: 15190283
    [No Abstract]   [Full Text] [Related]  

  • 25. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety.
    Bolton-Maggs PH; Cohen H
    Br J Haematol; 2013 Nov; 163(3):303-14. PubMed ID: 24032719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemovigilance and transfusion safety in France.
    Rouger P; Noizat-Pirenne F; Le Pennec PY
    Vox Sang; 2000; 78 Suppl 2():287-9. PubMed ID: 10938971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serious events: from statutory requirements to the implementation].
    Aullen JP; Lassale B; Verdot JJ
    Transfus Clin Biol; 2008 Nov; 15(5):217-22. PubMed ID: 18938098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Factsheets: support in the analysis of recipients' adverse reactions].
    Bazin A; Trophilme C; Py JY; Caldani C; Daurat G; Hauser L; Leconte des Floris MF; Moncharmont P; Pillonel J; Renaudier P; Richomme X; Sailliol A; Boudjedir K; Ounnoughene N; Sandid I; Vo-Mai MP; Carlier M
    Transfus Clin Biol; 2012 Nov; 19(4-5):187-94. PubMed ID: 22999854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The revision of the European blood directives: A major challenge for transfusion medicine.
    Folléa G; Aranko K;
    Transfus Clin Biol; 2015 Aug; 22(3):141-7. PubMed ID: 26056039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transfusion reactions in patients: haemovigilance reports to the Dutch National Haemovigilance Office in 2003].
    Wiersum-Osselton JC; Schipperus MR
    Ned Tijdschr Geneeskd; 2005 Nov; 149(47):2622-7. PubMed ID: 16355575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What are the rules and regulations for blood product transfusion in France?].
    Pélissier E; Bierling P
    Rev Prat; 2009 Jan; 59(1):90-2. PubMed ID: 19253890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Worldwide overview of existing haemovigilance systems.
    Faber JC
    Transfus Apher Sci; 2004 Oct; 31(2):99-110. PubMed ID: 15501414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the immediate transfusion reaction incident reporting system at the Brest University Hospital Center].
    Lozach P; Vicariot M; Le Niger C; Pomey MP; Lejeune B; Férec C; Chaperon J; Salmi LR
    Transfus Clin Biol; 2001 Aug; 8(4):343-9. PubMed ID: 11642026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results.
    Politis C; Wiersum JC; Richardson C; Robillard P; Jorgensen J; Renaudier P; Faber JC; Wood EM
    Vox Sang; 2016 Nov; 111(4):409-417. PubMed ID: 27658188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Postdonation information: the French fourth hemovigilance sub-process].
    Py JY; Sandid I; Jbilou S; Dupuis M; Adda R; Narbey D; Djoudi R
    Transfus Clin Biol; 2014 Nov; 21(4-5):216-22. PubMed ID: 25282491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Work of the European Haemovigilance Network (EHN).
    Faber JC
    Transfus Clin Biol; 2004 Feb; 11(1):2-10. PubMed ID: 14980542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International haemovigilance: what have we learned and what do we need to do next?
    Wood EM; Ang AL; Bisht A; Bolton-Maggs PH; Bokhorst AG; Flesland O; Land K; Wiersum-Osselton JC; Schipperus MR; Tiberghien P; Whitaker BI
    Transfus Med; 2019 Aug; 29(4):221-230. PubMed ID: 30729612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surveillance of tattoo-related adverse events by the EU RAPEX system and by national monitoring.
    Verdier C
    Curr Probl Dermatol; 2015; 48():210-7. PubMed ID: 25833647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Transfusion safety. Introduction and identifying the problem].
    Ambriz Fernández R
    Gac Med Mex; 2013; 149(1):73-80. PubMed ID: 23435078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [French haemovigilance from 1994 to nowadays: Evolution and prospects].
    Lassale B; Daurat G; Besse-Moreau M; Aullen JP
    Transfus Clin Biol; 2017 Sep; 24(3):268-272. PubMed ID: 28647104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.